Publication: Changes in the etiology of chronic liver disease by referral to a fibroscan center: rising prevalence of the non-alcoholic fatty liver disease” hepatology
Loading...
Files
Date
2022-12-01
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Background and Aim: Chronic liver disease (CLD) is a leading cause of morbidity and
mortality worldwide with wide etiological spectrum. FibroScan® is used for follow-up of
fibrosis and steatosis. This single center study aims to review the distribution of indications by
referral to FibroScan®.
Materials and Methods: Demographic characteristics, CLD etiologies, and FibroScan®
parameters of the patients, who were referred to our tertiary care center between 2013 and 2021
were retrospectively evaluated.
Results: Out of 9,345 patients, 4,946 (52.9%) were male, and median age was 48 [18-88]. Nonalcoholic fatty liver disease (NAFLD) was the most common indication (N= 4,768, 51.02%)
followed by hepatitis B (N=3,194, 34.18%) and hepatitis C (N=707, 7.57%). Adjusting for age,
sex, CLD etiology, the results revealed that patients with older age (Odds ratio (OR) =2.908,
confidence interval (CI): 2.597-3.256, P<0.001), and patients with hepatitis C (OR= 2.582;
CI=2.168-3.075; P<0.001), alcoholic liver disease (OR=2.019; CI=1.524-2.674, P<0.001),
autoimmune hepatitis (OR=2.138; CI=1.360-3.660, P<0.001) had increased odds of advanced
liver fibrosis compared to NAFLD.
Conclusion: NAFLD was the most common indication for referral to FibroScan®.
Description
Keywords
Chronic Liver Disease, Indications, Liver Fibrosis
Citation
Eris T., Hassan M., Hikal Y., Sawah E., Daneshgar F., TEKER SAYIN A. G., ÖZEL F., LÜLECİ N. E., Kaya E., YILMAZ Y., "Changes in the Etiology of Chronic Liver Disease by Referral to a Fibroscan Center: Rising Prevalence of the Non-Alcoholic Fatty Liver Disease” Hepatology", Hepatology Forum, cilt.3, sa.3, 2022